Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.10302 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Ehsan Mostafavi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Ira…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown.
Objective
To evaluate the efficacy and safety of a 2-dose regimen of FINLAY-FR-2 (cohort 1) and a 3-dose regimen of FINLAY-FR-2 with FINLAY-FR-1A (cohort 2) in Iranian adults. Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 6 cities in cohort 1 and 2 cities in cohort 2. Participants included individuals aged 18 to 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recent immunoglobulin or immunosuppressive therapy, and clinical presentation or laboratory-confirmed COVID-19 on enrollment. The study was conducted from April 26 to September 25, 2021.
Interventions
In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or placebo (n = 3462) were administered 28 days apart. In cohort 2, 2 doses of FINLAY-FR-2 plus 1 dose of FINLAY-FR-1A (n = 4340) or 3 placebo doses (n = 1081) were administered 28 days apart. Vaccinations were administered via intramuscular injection. Main Outcomes and Measures The primary outcome was polymerase chain reaction–confirmed symptomatic COVID-19 infection at least 14 days after vaccination completion. Other outcomes were adverse events and severe COVID-19. Intention-to-treat analysis was performed.
Results
In cohort 1 a total 17 319 individuals received 2 doses and in cohort 2 5521 received 3 doses of the vaccine or placebo. Cohort 1 comprised 60.1% men in the vaccine group and 59.1% men in the placebo group; cohort 2 included 59.8% men in the vaccine group and 59.9% in the placebo group. The mean (SD) age was 39.3 (11.9) years in cohort 1 and 39.7 (12.0) years in cohort 2, with no significant difference between the vaccine and placebo groups. The median follow-up time in cohort 1 was 100 (IQR, 96-106) days and, in cohort 2, 142 (137-148) days. In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) and 51 (4.3%) in cohort 2 (vaccine efficacy: 64.9%; 95% CI, 49.7%-59.5%). The incidence of serious adverse events was lower than 0.1%, with no vaccine-related deaths. Conclusions and Relevance In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of FINLAY-FR-2 and FINLAY-FR-1A, 2 doses of FINLAY-FR-2 plus the third dose of FINLAY-FR-1A showed acceptable vaccine efficacy against symptomatic COVID-19 as well as COVID-19–related severe infections. Vaccination was generally safe and well tolerated. Therefore, Soberana may have utility as an option for mass vaccination of the population, especially in resource-limited settings, because of its storage condition and affordable price. Trial Registration isrctn.org Identifier: IRCT20210303050558N1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
- School of Public Health, Brown University, Providence, Rhode Island.
- Centre on Drug Policy Evaluation, St. Michael's Hospital, Toronto, Ontario, Canada.
- The Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada.
- Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Zitieren
APA
Mostafavi, E., Eybpoosh, S., Karamouzian, M., Khalili, M., Haji-Maghsoudi, S., Salehi-Vaziri, M., Khamesipour, A., Jalali, T., Nakhaeizadeh, M., Sharifi, H., Mansoori, Y., Keramat, F., Ghodrati, S., Javanian, M., Doroud, D., Omrani, M. D., Asadi, H., Pouriayevali, M. H., Ghasemian, R., …, & Soberana Study Group (2023). Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.10302
Vancouver
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.10302
BibTeX
@article{Mostafavi2023,
author = {Mostafavi, Ehsan and Eybpoosh, Sana and Karamouzian, Mohammad and Khalili, Malahat and Haji-Maghsoudi, Saiedeh and Salehi-Vaziri, Mostafa and Khamesipour, Ali and Jalali, Tahmineh and Nakhaeizadeh, Mehran and Sharifi, Hamid and Mansoori, Yasaman and Keramat, Fariba and Ghodrati, Samad and Javanian, Mostafa and Doroud, Delaram and Omrani, Mir Davood and Asadi, Hassan and Pouriayevali, Mohammad Hassan and Ghasemian, Roya and Farshidi, Hossein and Pourahmad, Morteza and Ghasemzadeh, Iman and Mounesan, Leila and Darvishian, Maryam and Mirjalili, Mohamad Reza and Toledo-Romani, Maria Eugenia and Valenzuela-Silva, Carmen and Verez-Bencomo, Vicente and Gouya, Mohammad Mehdi and Emadi-Koochak, Hamid and Haghdoost, Ali Akbar and Biglari, Alireza and Soberana Study Group, Soberana Study Group},
title = {Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.10302}
}
EUVIMED